Northern Biologics launched in Toronto in late 2014 with a vision to source, discover and develop first-in-class antibody therapeutics for oncology. Initially funded with a combined $40 million in equity from Versant Ventures and collaboration funding from Celgene, Northern Biologics has brought in several highly innovative antibodies targeting novel effector molecules in validated cancer pathways. In 2016, Northern expanded its portfolio through the acquisition of MSC-1, a first-in-class antibody targeting leukemia inhibitory factor (LIF), a key immunosuppressive cytokine in the tumor microenvironment. As exemplified by the ongoing Phase I trial of MSC-1, our translational and clinical strategies are designed to confirm the mechanisms of action of our antibodies and precisely target patients who can benefit most from our therapies.
